Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3000202 dose-ranging study in moderate to severe systemic lupus erythematosus
NL-OMON61713Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing BI 3000202 dose regimen arm(s) with Placebo arm (2 arms). Primary endpoint: Achievement of SRI-4 response at Week 32. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON61713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61713.